Intrathecal pemetrexed for leptomeningeal metastasis from lung adenocarcinoma: a clinical efficacy and multiplex liquid proteomics exploration study
Open Access
- 24 September 2025
- journal article
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 30 (10)
Abstract
Background: Leptomeningeal metastasis (LM) is an advanced complication of lung cancer with a poor prognosis. It remains unknown whether intrathecal pemetrexed (IP) can improve the outcomes of patients with LM from lung adenocarcinoma (LUAD). This study explored the efficacy of intrathecal pemetrexed (IP) and proteomic biomarkers in LM from LUAD. Patients and Methods: We conducted a retrospective survival analysis of 157 confirmed LM patients (54 IP vs 103 non-IP). To balance the baseline, propensity score matching (PSM) was implemented. We investigated clinical baseline characteristics and treatment factors to identify those influencing the outcomes of LM patients. Plasma and cerebrospinal fluid (CSF) samples underwent proteomic profiling using Olink Immuno-Oncology panels to identify IP response biomarkers and build a prediction model. Results: After PSM, 82 patients were included in two matched cohort (41 IP vs 41 non-IP). IP treatment (HR = 0.427, P = .022) and ECOG performance status (HR = 2.737, P = .005) were independent predictors of overall survival (OS). Stratified analysis showed IP significantly improved OS in patients with poor performance status (ECOG 3-4: IP vs non-IP, 11.2 vs 2.5 months, P = .0029). Proteomics revealed low plasma MCP-2 (AUC = 0.873) and high CSF ARG1 (AUC = 0.875) levels distinguished IP responders from nonresponders. Conclusions: IP therapy improves OS in LUAD patients with LM, particularly offering significant benefit as salvage treatment for those with ECOG 3-4. Proteomic analysis suggests plasma MCP-2 and CSF ARG1 are promising predictive biomarkers for IP response. The small sample size in biomarker analysis may limit these findings, necessitating validation through multicenter studies.Keywords
Funding Information
- National Natural Science Foundation of China (82273323)
This publication has 35 references indexed in Scilit:
- Intrathecal pemetrexed improves survival outcomes in previously treated EGFR-mutant advanced non-small-cell lung cancer with leptomeningeal metastasesHeliyon, 2024
- Efficacy and safety of intrathecal pemetrexed for TKI-failed leptomeningeal metastases from EGFR+ NSCLC: an expanded, single-arm, phase II clinical trialESMO Open, 2024
- The role of tumor-associated macrophages in lung cancer: From mechanism to small molecule therapyBiomedicine & Pharmacotherapy, 2023
- Effects of intrathecal pemetrexed on the survival of patients with leptomeningeal metastasis from lung adenocarcinoma: a propensity score matching analysisJournal of Neuro-Oncology, 2023
- The Spectrum of Headache in Leptomeningeal Metastases: A Comprehensive Review with Clinical Management GuidelinesCurrent Pain and Headache Reports, 2023
- Leptomeningeal metastasis from solid tumours: EANO–ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upESMO Open, 2023
- Proteomics to study cancer immunity and improve treatmentSeminars in Immunopathology, 2023
- Safety, Pharmacokinetic and Clinical Activity of Intrathecal Chemotherapy With Pemetrexed via the Ommaya Reservoir for Leptomeningeal Metastases From Lung Adenocarcinoma: A Prospective Phase I StudyClinical Lung Cancer, 2022
- Mechanisms, Management and Prevention of Pemetrexed-Related ToxicityDrug Safety, 2021
- MCP2 activates NF‐κB signaling pathway promoting the migration and invasion of ESCC cellsCell Biology International, 2017